New drug duo targets genetic flaws in Tough-to-Treat head and neck cancer
NCT ID NCT04997902
Summary
This early-phase trial tested the safety and initial effectiveness of a two-drug combination (tipifarnib and alpelisib) for adults with advanced head and neck cancer that had returned or spread. The study focused on patients whose tumors had specific genetic markers (HRAS or PIK3CA). The main goals were to find a safe dose and see if the drugs could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute (Head and Neck Cancer Treatment Center)
Boston, Massachusetts, 02215, United States
-
Johns Hopkins University School of Medicine (Sidney Kimmel Comprehensive Cancer Center)
Baltimore, Maryland, 21231, United States
-
Lake Nona DDU (Florida Cancer Specialists)
Orlando, Florida, 32827, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
UT Southwestern Medical Center (Harold C. Simmons Comprehensive Cancer Center)
Dallas, Texas, 75390, United States
-
University of Maryland School of Medicine (Marlene and Stewart Greenebaum Comprehensive Cancer Center)
Baltimore, Maryland, 21201, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States
-
Washington University, School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.